What You Should Know:
- Personalis, Inc., a leader in advanced genomics for cancer, and ClearNote Health, Inc., a pioneer in epigenomic technologies, today unveiled an alliance through which Personalis will expand its pharmaceutical service offerings by distributing ClearNote’s cutting-edge epigenomic 5-hydroxymethylcytosine (5hmC) platform.
Revolutionizing Cancer Detection and Treatment: ClearNote Health’s Epigenomics Platform
ClearNote Health’s Epigenomics Platform is a groundbreaking tool for cancer detection, providing real-time insights into disease-specific pathways. Using artificial intelligence and monitoring changes in 5hmC levels, the platform can detect cancer early, track disease progression, identify drug targets, and understand resistance mechanisms. This invaluable information aids in optimizing drug development programs and delivering more effective treatments to patients.
The platform tracks changes in gene activation and regulation by examining the 5hmC landscape in plasma-derived cell-free DNA, contributing to real-time monitoring of cancer therapies in clinical trials and enhancing understanding of drug resistance mechanisms. The partnership signifies a pivotal moment in cancer research, combining the strengths of both companies to offer unparalleled solutions in the biopharmaceutical industry.
“We have built a unique pharma channel based on our industry-leading tissue and MRD assays and ClearNote Health’s blood-based epigenomic approach is complementary to our offering as it helps our customers deepen their understanding of a patient’s response to immunotherapies,” said Chris Hall, CEO and President of Personalis. “Commercial partnerships such as this broaden our portfolio and are expected to appeal to a wide range of biopharma customers and accelerate our revenue growth.”
